Two groups can have similar results without a trial proving that the treatments are equivalent. This hCG comparison illustrates that distinction. Primary report
Study snapshot
Two hundred patients undergoing ICSI were randomized to recombinant or urinary hCG for final oocyte maturation. The report found similar maturity and fertilization results. Clinical pregnancy was reported in 34% and 39% of cycles, respectively, without a statistically significant difference. The authors described the preparations as similarly effective in this setting. Primary report
Our appraisal: uncertainty determines what similarity means
The point estimates are only part of the comparison. A confidence interval shows the range of differences compatible with the data under the model. Without that precision information, an apparently small observed gap cannot establish that clinically important differences have been excluded.
Formal equivalence and noninferiority also require an explicit margin and a design suited to that purpose. The word “similar” in a conclusion should not be treated as evidence that these requirements were met. Review must examine the protocol rather than infer its statistical objective from reassuring language.
Another boundary concerns formulation. The results apply to the specific preparations and clinical process studied. They do not demonstrate that every product labeled hCG has matching quality, exposure, or performance.
Finally, oocyte maturity, fertilization, clinical pregnancy, and live birth are different stages. A complete clinical appraisal should track progression through the pathway and retain complications, cancellations, and missing outcomes. This research summary is not a substitution instruction or a self-administered fertility protocol.
Frequently asked questions
Was the comparison randomized?
The report describes randomized assignment.
Was a significant clinical-pregnancy difference found?
No. The reported comparison was nonsignificant.
Does that prove formal equivalence?
No. The design, margin, and uncertainty must support that conclusion.
Is fertilization the same endpoint as live birth?
No. They occur at different stages.
Can the findings validate every hCG product?
No. Product identity and quality are separate questions.
Why inspect cancellations and missing outcomes?
They can change which participants remain in each reported denominator.
What should the final appraisal preserve?
The studied formulations, clinical setting, endpoint definitions, uncertainty, and safety findings.